Skip to main content
Top
Published in: Annals of Hematology 2/2014

01-02-2014 | Original Article

Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas

Authors: Beatriz Heredia-Galvez, Javier Ruiz-Cosano, Daniel Torres-Moreno, Ignacio Español, María José Morales-Lara, Elena Pérez-Ceballos, Rocío González-Conejero, Rocío Gutiérrez-Cívicos, Vicente Vicente, Miguel Pérez-Guillermo, Pablo Conesa-Zamora

Published in: Annals of Hematology | Issue 2/2014

Login to get access

Abstract

The TRAILR1/TRAIL system is implicated in the induction of the extrinsic apoptotic pathway and constitutes an emerging target in cancer therapeutics. The objective of this study is to assess lymphoma risk associated with certain polymorphisms in TRAILR1 and TRAIL1 genes. DNA was extracted from 381 subjects (190 lymphoma cases and 191 matched controls) and genotyped for polymorphisms rs20576, rs2230229 and rs20575 in TRAILR1 and rs12488654 in TRAIL gene. In contrast to TRAILR1 polymorphisms, the genotype distribution of rs12488654 in TRAIL gene was different between cases and controls, A allele carriers (CA/AA) being much more common in the cases with different lymphoma types (follicular, 45 %; diffuse large B cell, 45.2 % and Hodgkin lymphomas, 40 %) than in controls (15.7 %) (odds ratio (OR), 3.5; CI, 2.1–5.9; p < 0.001; OR, 3.5; CI, 1.6–7.9; p = 0.001; OR, 2.9; CI, 1.1–7.5; p = 0.027, respectively). This effect was consistently independent of the association with the TRAILR1 polymorphisms studied, as demonstrated by linkage disequilibrium and haplotype analyses. This study is the first one to report an association between a TRAIL polymorphism and lymphoma risk and suggests a possible role of TRAIL in B cell lymphomagenesis.
Literature
1.
go back to reference Frank B, Shanmugam KS, Beckmann L, Hemminki K, Brenner H, Hoffmeister M, Chang-Claude J, Burwinkel B (2006) Death receptor 4 variants and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 15:2002–2005PubMedCrossRef Frank B, Shanmugam KS, Beckmann L, Hemminki K, Brenner H, Hoffmeister M, Chang-Claude J, Burwinkel B (2006) Death receptor 4 variants and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 15:2002–2005PubMedCrossRef
2.
go back to reference Hazra A, Chamberlain RM, Grossman HB, Zhu Y, Spitz MR, Wu X (2003) Death receptor 4 and bladder cancer risk. Cancer Res 63:1157–1159PubMed Hazra A, Chamberlain RM, Grossman HB, Zhu Y, Spitz MR, Wu X (2003) Death receptor 4 and bladder cancer risk. Cancer Res 63:1157–1159PubMed
3.
go back to reference Langsenlehner T, Langsenlehner U, Renner W, Kapp KS, Krippl P, Hofmann G, Clar H, Pummer K, Mayer R (2008) The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases. Prostate 68:264–268PubMedCrossRef Langsenlehner T, Langsenlehner U, Renner W, Kapp KS, Krippl P, Hofmann G, Clar H, Pummer K, Mayer R (2008) The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases. Prostate 68:264–268PubMedCrossRef
4.
go back to reference Chen B, Liu S, Wang XLXW, Li Y, Zhao WH, Wu JQ (2009) TRAIL-R1 polymorphisms and cancer susceptibility: an evidence-based meta-analysis. Eur J Cancer 45:2598–2605PubMedCrossRef Chen B, Liu S, Wang XLXW, Li Y, Zhao WH, Wu JQ (2009) TRAIL-R1 polymorphisms and cancer susceptibility: an evidence-based meta-analysis. Eur J Cancer 45:2598–2605PubMedCrossRef
5.
go back to reference Wolf S, Mertens D, Pscherer A, Schroeter P, Winkler D, Gröne HJ, Hofele C, Hemminki K, Kumar R, Steineck G, Döhner H, Stilgenbauer S, Lichter P (2006) Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Cancer 118:1831–1835PubMedCrossRef Wolf S, Mertens D, Pscherer A, Schroeter P, Winkler D, Gröne HJ, Hofele C, Hemminki K, Kumar R, Steineck G, Döhner H, Stilgenbauer S, Lichter P (2006) Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Cancer 118:1831–1835PubMedCrossRef
6.
go back to reference Fernandez V, Jares P, Bea S, Salaverria I, Guino E, de Sanjosé S, Colomer D, Ott G, Montserrat E, Campo E (2004) Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms. Haematologica 89:1322–1331PubMed Fernandez V, Jares P, Bea S, Salaverria I, Guino E, de Sanjosé S, Colomer D, Ott G, Montserrat E, Campo E (2004) Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms. Haematologica 89:1322–1331PubMed
7.
go back to reference Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, Lee JH, Han SY, Park JY, Oh RR, Kang CS, Kim KM, Jang JJ, Nam SW, Lee JY, Yoo NJ (2001) Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin’s lymphoma. Oncogene 20:399–403PubMedCrossRef Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, Lee JH, Han SY, Park JY, Oh RR, Kang CS, Kim KM, Jang JJ, Nam SW, Lee JY, Yoo NJ (2001) Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin’s lymphoma. Oncogene 20:399–403PubMedCrossRef
8.
go back to reference Pal R, Gochhait S, Chattopadhyay S, Gupta P, Prakash N, Agarwal G, Chaturvedi A, Husain N, Husain SA, Bamezai RN (2011) Functional implication of TRAIL −716 C/T promoter polymorphism on its in vitro and in vivo expression and the susceptibility to sporadic breast tumor. Breast Cancer Res Treat 126:333–343PubMedCrossRef Pal R, Gochhait S, Chattopadhyay S, Gupta P, Prakash N, Agarwal G, Chaturvedi A, Husain N, Husain SA, Bamezai RN (2011) Functional implication of TRAIL −716 C/T promoter polymorphism on its in vitro and in vivo expression and the susceptibility to sporadic breast tumor. Breast Cancer Res Treat 126:333–343PubMedCrossRef
9.
go back to reference Ruiz-Cosano J, Conesa-Zamora P, González-Conejero R, Pérez-Ceballos E, Martínez-Francés A, Vicente V, Pérez-Guillermo M (2012) Role of GSTT1 and M1 null genotypes as risk factors for B-cell lymphoma: influence of geographical factors and occupational exposure. Mol Carcinog 51:508–513PubMedCrossRef Ruiz-Cosano J, Conesa-Zamora P, González-Conejero R, Pérez-Ceballos E, Martínez-Francés A, Vicente V, Pérez-Guillermo M (2012) Role of GSTT1 and M1 null genotypes as risk factors for B-cell lymphoma: influence of geographical factors and occupational exposure. Mol Carcinog 51:508–513PubMedCrossRef
10.
go back to reference Morales-Lara MJ, Cañete JD, Torres-Moreno D, Hernández MV, Pedrero F, Celis R, García-Simón MS, Conesa-Zamora P (2012) Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 79:591–596PubMedCrossRef Morales-Lara MJ, Cañete JD, Torres-Moreno D, Hernández MV, Pedrero F, Celis R, García-Simón MS, Conesa-Zamora P (2012) Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 79:591–596PubMedCrossRef
11.
go back to reference Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, He L, Shi Y (2009) A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis. Cell Res 19:519–23. http://analysis2.bio-x.cn/myAnalysis.php. Accessed 12 Jan 2013 Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, He L, Shi Y (2009) A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis. Cell Res 19:519–23. http://​analysis2.​bio-x.​cn/​myAnalysis.​php. Accessed 12 Jan 2013
12.
go back to reference Mitelman F, Mertens F, Johansson B (1997) A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 15:417–474PubMedCrossRef Mitelman F, Mertens F, Johansson B (1997) A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 15:417–474PubMedCrossRef
13.
go back to reference Monni O, Joensuu H, Franssila K, Knuutila S (1996) DNA copy number changes in diffuse large B-cell lymphoma—comparative genomic hybridization study. Blood 87:5269–5278PubMed Monni O, Joensuu H, Franssila K, Knuutila S (1996) DNA copy number changes in diffuse large B-cell lymphoma—comparative genomic hybridization study. Blood 87:5269–5278PubMed
14.
go back to reference Liang XS, Caporaso N, McMaster ML, Ng D, Landgren O, Yeager M, Chanock S, Goldin LR (2009) Common genetic variants in candidate genes and risk of familial lymphoid malignancies. Br J Haematol 146:418–423PubMedCrossRef Liang XS, Caporaso N, McMaster ML, Ng D, Landgren O, Yeager M, Chanock S, Goldin LR (2009) Common genetic variants in candidate genes and risk of familial lymphoid malignancies. Br J Haematol 146:418–423PubMedCrossRef
15.
go back to reference Nogai H, Dörken B, Lenz G (2011) Pathogenesis of non-Hodgkin’s lymphoma. J Clin Oncol 29:1803–1811PubMedCrossRef Nogai H, Dörken B, Lenz G (2011) Pathogenesis of non-Hodgkin’s lymphoma. J Clin Oncol 29:1803–1811PubMedCrossRef
16.
go back to reference Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS (2007) Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res 13:4556–4564PubMedCrossRef Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS (2007) Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res 13:4556–4564PubMedCrossRef
Metadata
Title
Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas
Authors
Beatriz Heredia-Galvez
Javier Ruiz-Cosano
Daniel Torres-Moreno
Ignacio Español
María José Morales-Lara
Elena Pérez-Ceballos
Rocío González-Conejero
Rocío Gutiérrez-Cívicos
Vicente Vicente
Miguel Pérez-Guillermo
Pablo Conesa-Zamora
Publication date
01-02-2014
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 2/2014
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1864-4

Other articles of this Issue 2/2014

Annals of Hematology 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.